Cancer and fertility preservation: fertility preservation in breast cancer patients

Breast Cancer Research

Table 1 Incidence of amenorrhea induced by the most commonly used chemotherapy regimens in breast cancer

						Rate of amenorrhea
Reference	Year	Patients (n)	Chemotherapy regimen	Duration of treatment (months)	Follow-up to definite amenorrhea (months)	Percentage	Age (years)
Goldhirsch and colleagues [4]	1990	541	CMF	1	9	14/34	<40/>40
		387		6		33/81	<40/>40
Bines and colleagues [5]	1996	3,628	CMF	3 to 24	12	40/76	<40/>40
Levine and colleagues [6]	1998	359	CMF	6	NA	42.6
		132	FEC	6
Goodwin and colleagues [7]	1999	83	CMF	6	12	55.6
		25	FEC	6		64.6
Nabholtz and colleagues [8]	2002	745	ACD	6	33	51.4
		746	FAC	6
Fornier and colleagues [9]	2005	84	AC-T/D	6	12	13
		82	AC-T/D + tamoxifen			17
Martin and colleagues [10]	2005	420	ACD	6	NA	61.7
		403	FAC			52.4
Venturini and colleagues [11]	2005	503	FEC	4	120	64
Petrek and colleagues [12]	2006	120	AC	4	36	53
		168	ACT	6		42
		83	CMF	8		82
		38	FAC	6		NA
		34	FACT	6		NA
		19	ACD	6		45
Tham and colleagues [13]	2007	75	AC	4	12	44/81	<40/>40
		116	AC + T/D	4 + 3		61/85	<40/>40
Total		8,681

AC, adriamycin (doxorubicin), and cyclophosphamide; ACD, adriamycin (doxurubicin), cyclophosphamide and docetaxel; AC-T/D, adriamycin (doxorubicin), cyclophosphamide and taxol (paclitaxel)/docetaxel; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; FAC, 5-fluorouracil, adriamycin (doxorubicin), and cyclophosphamide; FACT, 5-fluorouracil, adriamycin (doxorubicin), cyclophosphamide and taxol (paclitaxel); FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; NA, not available.

ISSN: 1465-542X